DaVita, RenalytixAI to launch program aimed at earlier kidney disease detection
RenalytixAI and DaVita are collaborating on a program that will use an artificial intelligence-based diagnostic tool to aid in identifying individuals at risk for kidney disease or kidney failure.
The tool by RenalytixAI, known as KidneyIntelX, generates a patient-specific risk score utilizing a machine-learning algorithm based on blood biomarkers and electronic health records (Healio Nephrology previously reported on how KidneyIntelX could be used to predict adverse kidney outcomes in patients hospitalized with COVID-19).
According to a press release, the program seeks to ensure patients receive earlier interventions and will provide integrated kidney care through DaVita.
“This is the first clinical-grade program that delivers advanced early-stage prognosis and risk stratification, combined with actionable care management right to the primary care level where the majority of kidney disease patients are being seen,” James McCullough, CEO of Renalytix AI, said in the release. “Making fundamental change in kidney disease health economics and outcomes must begin with providing a clear, actionable understanding of disease progression risk.”
Javier Rodriguez, CEO of DaVita, also commented on the program in the release.
“Almost 50% of people whose kidneys fail find out after it is too late, and we are on a mission to change that,” he said. “Our partnership with RenalytixAI could allow us to help slow disease progression for the millions of people living with kidney disease.”
With the expansion of the program, the companies intend to work with “health care providers and [payers] to drive kidney disease patient care innovation, cost efficiencies and improve quality of life,” according to the release.